Sorafenib with ASC-J9®synergistically Suppresses the HCC Progressionviaaltering the Pstat3-Ccl2/bcl2 Signals

Junjie Xu,Hui Lin,Gonghui Li,Yin Sun,Liang Shi,Wen-Lung Ma,Jiang Chen,Xiujun Cai,Chawnshang Chang
DOI: https://doi.org/10.1002/ijc.30446
2016-01-01
International Journal of Cancer
Abstract:Sorafenib is currently used as a standard treatment to suppress the progression of hepatocellular carcinoma (HCC), especially in advanced stages. However, patients who receive Sorafenib treatment eventually develop resistance without clear mechanisms. There is a great need for better efficacy of Sorafenib treatment in combination with other therapies. Here, we demonstrated that the treatment combining Sorafenib with ASC-J9® could synergistically suppress HCC progression via altering cell-cycle regulation, apoptosis and invasion. Mechanism dissection suggests that while Sorafenib impacts little or even slightly increases the activated/phosphorylated STAT3 (p-STAT3), a key stimulator to promote the HCC progression, adding ASC-J9® significantly suppresses the p-STAT3 expression and its downstream genes including CCL2 and Bcl2. Interrupting these signals via constitutively active STAT3 partially reverses the synergistic suppression of Sorafenib-ASC-J9® combination on HCC progression. In vivo studies further confirmed the synergistic effect of Sorafenib-ASC-J9® combination. Together, these results suggest the newly developed Sorafenib-ASC-J9® combination is a novel therapy to better suppress HCC progression.
What problem does this paper attempt to address?